Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-11-16

FDA Approved: CARBAGLU — Supplemental Application (Recordati Rare Diseases)

View source ↗

Summary

The FDA approved a supplemental application for CARBAGLU (carglumic acid) from Recordati Rare Diseases, expanding its labeling for the treatment of hyperammonem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Carbaglu (carglumic acid)

Snippet

SUPPL AP for CARBAGLU (CARGLUMIC ACID)